Clinical trial · Observational
An Observational Study Of Indian Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin
NCT00776659CI-TRIAL-00012682terminatedResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): See termination reason in detailed description.
Summary
Brief summary (as posted)
To generate the following data from patients with early breast cancer treated with Aromasin® in the adjuvant setting in India. * Efficacy of the treatment with Aromasin® * Safety of the treatment with Aromasin®
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Neoplasms | Breast Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Aromasin | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Observational
- interventionNames
- Other: Aromasin
Primary outcomes (7)
- measure
- Number of Participants With Locoregional/Distant Recurrence of Primary Breast Cancer
- timeFrame
- Baseline until locoregional/distant recurrence of primary breast cancer (up to Year 3.5)
- description
- Locoregional recurrence was defined as any recurrence of the breast cancer in the ipsilateral breast, chest wall or axillary lymph nodes.
- measure
- Number of Participants With Appearance of Second Primary or Contralateral Breast Cancer
- timeFrame
- Baseline until appearance of second primary or contralateral breast cancer (up to Year 3.5)
- measure
- Number of Participants Who Died
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with early breast cancer receiving adjuvant therapy with Aromasin® will be eligible. Exclusion Criteria: * Patients presenting with in situ cancers, recurrent or metastatic breast cancer, or a 2nd primary will not be included. * Patients with a known hypersensitivity to Exemestane or its metabolites will also not be included.
References
Publications (0)
Data not yet available
No reference posted for this study.